Loading...

Nika BioTechnology, Inc.

NIKAPNK
Healthcare
Drug Manufacturers - Specialty & Generic
$0.35
$-0.60(-62.80%)

Nika BioTechnology, Inc. (NIKA) Stock Competitors & Peer Comparison

See (NIKA) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
NIKA$0.35-62.80%972.9MN/AN/AN/A
MKGAF$131.08-1.56%58.3B17.46$7.68+1.87%
MKKGY$25.35-3.74%55.6B16.62$1.54+1.95%
TKPHF$31.00+1.31%48.4B53.45$0.58+4.28%
IPSEY$34.09+0.96%45.1B21.85$1.56+0.76%
HLNCF$4.68-4.78%43.6B22.11$0.22+2.53%
SDZNY$62.05-1.16%26.9B120.21$0.52+1.16%
ESALY$61.51-2.11%17.6B20.54$3.00N/A
TEVJF$14.32+0.00%16.4B-95.47-$0.15N/A
SGIOF$17.96+1.47%15.1B13.01$1.36+4.60%
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

NIKA vs MKGAF Comparison August 2025

NIKA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NIKA stands at 972.9M. In comparison, MKGAF has a market cap of 58.3B. Regarding current trading prices, NIKA is priced at $0.35, while MKGAF trades at $131.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NIKA currently has a P/E ratio of N/A, whereas MKGAF's P/E ratio is 17.46. In terms of profitability, NIKA's ROE is +0.23%, compared to MKGAF's ROE of +0.10%. Regarding short-term risk, NIKA is less volatile compared to MKGAF. This indicates potentially lower risk in terms of short-term price fluctuations for NIKA.Check MKGAF's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;